{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:14:05Z","timestamp":1790252045408,"version":"4.1.0"},"reference-count":10,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Cangrelor, a potent intravenous P2Y12 platelet inhibitor, has demonstrated effectiveness in reducing ischemic events without a corresponding increase in severe bleeding during percutaneous coronary intervention, as evidenced by the CHAMPION-PHOENIX trial. Its off-label role as a bridging antiplatelet agent for patients facing high thrombotic risks who must temporarily stop oral P2Y12 inhibitor therapy further underscores its clinical utility. This is the first case series to shed light on the application of cangrelor in cancer patients needing to pause dual antiplatelet therapy for a range of medical interventions, marking it as a pioneering effort in this domain. The inclusion of patients with a variety of cancer types and cardiovascular conditions in this series underlines the adaptability and critical role of cangrelor in managing the dual challenges of bleeding risk and the need for uninterrupted antiplatelet protection. By offering a bridge for high-risk cancer patients who have recently undergone percutaneous coronary intervention and need to halt oral P2Y12 inhibitors temporarily, cangrelor presents a practical solution. Early findings indicate it can be discontinued safely 2-4 h before medical procedures, allowing for the effective reintroduction of oral P2Y12 inhibitors without adverse effects. This evidence calls for expanded research to validate and extend these preliminary observations, emphasizing the importance of further investigation into cangrelor's applications in complex patient care scenarios.<\/jats:p>","DOI":"10.3389\/fcvm.2024.1337957","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T05:35:57Z","timestamp":1709184957000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Navigating P2Y12 inhibition in the labyrinth of cardio-oncology care: cangrelor bridging in patients with cancer"],"prefix":"10.3389","volume":"11","author":[{"given":"Abdelrahman","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poonam","family":"Jewani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Bourdillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efstratios","family":"Koutroumpakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaden","family":"Khalaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Charitakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Marmagkiolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Deswal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cezar","family":"Iliescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","article-title":"Effect of platelet inhibition with cangrelor during PCI on ischemic events","volume":"368","author":"Bhatt","year":"2013","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1001\/jama.2011.2002","article-title":"Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial","volume":"307","author":"Angiolillo","year":"2012","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1177\/0897190018795343","article-title":"A case report of cangrelor bridge therapy for a diagnostic bronchoscopy with biopsy","volume":"33","author":"Calnan","year":"2020","journal-title":"J Pharm Pract"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","article-title":"Intravenous platelet blockade with cangrelor during PCI","volume":"361","author":"Bhatt","year":"2009","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1056\/NEJMoa0908628","article-title":"Platelet inhibition with cangrelor in patients undergoing PCI","volume":"361","author":"Harrington","year":"2009","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"E202","DOI":"10.1002\/ccd.26379","article-title":"SCAI expert consensus statement: evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the Cardiological Society of India, and Sociedad Latino Americana de Cardiolog\u0131a Intervencionista)","volume":"87","author":"Iliescu","year":"2016","journal-title":"Catheter Cardiovasc Interv"},{"key":"B7","first-page":"429","article-title":"Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP). Results of a randomized multicenter trial by the Italian cooperative group for TTP","volume":"82","author":"Bobbio-Pallavicini","year":"1997","journal-title":"Haematologica"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/suac011.081","article-title":"C83\u00b0 use of cangrelor in a 63 years old men suffering from acute inferior ST\u2013elevation myocardial infarction and severe idiopathic thrombocytopenic purpura: a case report","volume":"24","author":"Cocozza","year":"2022","journal-title":"Eur Heart J Suppl"},{"key":"B9","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/phar.2219","article-title":"Use of cangrelor as a bridge to left ventricular assist device implantation in a patient with a recent drug-eluting stent who developed acute tirofiban-related thrombocytopenia","volume":"39","author":"Kabadi","year":"2019","journal-title":"Pharmacotherapy"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e005635","DOI":"10.1161\/CIRCINTERVENTIONS.117.005635","article-title":"Incidence, predictors, and outcomes of acquired thrombocytopenia after percutaneous coronary intervention: a pooled, patient-level analysis of the CHAMPION trials (cangrelor versus standard therapy to achieve optimal management of platelet inhibition)","volume":"11","author":"Groves","year":"2018","journal-title":"Circ Cardiovasc Interv"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1337957\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T05:35:59Z","timestamp":1709184959000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1337957\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,29]]},"references-count":10,"alternative-id":["10.3389\/fcvm.2024.1337957"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2024.1337957","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,29]]},"article-number":"1337957"}}